prescription drugs
Free drug information service 
All available medical information about prescription drugs 


Magnevist - Action And Clinical Pharmacology
Magnevist was developed as a contrast agent for diagnostic use in magnetic resonance imaging (MRI). Gadolinium is a rare earth element. Its ion (Gd++ has 7 unpaired electrons and, therefore, shows paramagnetic properties. Gd++has a strong effect on the hydrogen-proton spin-lattice relaxation time (T1), which causes the observed contrast enhancement in MRI scans. By chelation of Gd++with diethylenetriamine pentaacetic acid (DTPA), a strongly paramagnetic, well-tolerated, stable complex (gadopentetate dimeglumine salt) is obtained.

The free gadolinium ion is unsuitable for clinical use due to high toxicity, however, the metal chelate is metabolically inert. The organic component of the chelate is not measurably metabolized and the metal does not dissociate. After i.v. injection of Magnevist, the meglumine ion completely dissociates from the gadopentetate. The hydrophylic chelate is distributed only in the extracellular water and does not cross the intact blood-brain barrier. Gadopentetate is excreted unchanged in the urine. It is rapidly eliminated by the kidneys with a clearance identical to that of inulin (no tubular reabsorption).

Pharmacokinetics: The pharmacokinetic profile of i.v. administered Magnevist in normal subjects conforms to a 2 compartment open model with a mean distribution half-life of about 0.2 hours and a mean elimination half-life of about 1.6 hours. Approximately 80% of the dose was excreted in the urine within 6 hours and 93% within 24 hours post injection of a 0.1 mmol/kg dose. Excretion in the feces amounted to <0.1% over 5 days. There was no detectable biotransformation, dissociation or decomposition of gadopentetate.

Magnevist has no pharmacodynamic effect when administered as indicated with the exception of slightly increased plasma osmolality.

Magnevist - Indications And Clinical Uses
By i.v. injection, for contrast enhancement during cranial and spinal MRI investigations in adults and children, to detect lesions associated with abnormal vascularity, or those thought to alter the blood-brain barrier.

Magnevist - Contra-Indications
Should not be administered to patients who are known or suspected of being hypersensitive to it.

Magnevist - Manufacturers' Warnings In Clinical States
The decision to use Magnevist must be made after careful evaluation of the risk-benefit in patients with a history of allergic disposition or bronchial asthma, since experience shows that these patients suffer more frequently than others from hypersensitivity reactions.

In very rare cases anaphylactoid reactions, including anaphylactic shock, may occur after i.v. injection of Magnevist. It is important for prompt action in the event of such incidents to be familiar with the practice of emergency measures. To permit immediate countermeasures to be taken in emergencies, appropriate drugs and instruments (e.g., endotracheal tube and ventilator) should be readily available.

Deoxygenated sickle cell erythrocytes have been shown in in vitro studies to align perpendicular to a magnetic field which may result in vaso-occlusive complications in vivo. The enhancement of magnetic moment by Magnevist may possibly potentiate sickle erythrocyte alignment. Magnevist in patients with sickle cell anemia and other hemoglobinopathies has not been studied.

No studies have been conducted in children with severe renal or hepatic dysfunction, clinically unstable or uncontrolled hypertension, or in premature infants.

MRI procedures which involve the use of Magnevist by injection should be carried out by physicians who have the prerequisite training and a thorough knowledge of the particular procedure to be performed.

Magnevist - Precautions
General: Magnevist is to be administered strictly by i.v. injection. It will cause tissue irritation and pain if administered extravascularly or if it leaks interstitially.

A sweet taste may be experienced briefly by patients receiving a bolus injection of Magnevist i.v.

Hemolytic States: Magnevist alters red blood cell morphology resulting in transient, slight, extravascular (splenic) hemolysis with increased serum iron and total bilirubin levels. Although this effect was of no clinical significance during clinical trials, caution is advised in patients with hepatic disease and/or hemolytic states.

Convulsive States: While there is no evidence suggesting that Magnevist directly precipitates convulsion, the possibility that it may decrease the convulsive threshold in susceptible patients cannot be ruled out. Precautionary measures should be taken with patients predisposed to seizure, e.g., close monitoring and availability of injectable anticonvulsants (see Dosage).

Pregnancy: There are no studies on the use of Magnevist in pregnant women. Magnevist should not be used during human pregnancy unless the potential benefit justifies the potential risk to the fetus.

Lactation: Transfer of Magnevist into the milk of lactating mothers can occur. Thus breast-feeding should be interrupted for 24 hours postadministration of Magnevist and the milk discarded during this period.

Geriatrics: No special precautions are required for elderly patients.

Magnevist- Adverse Reactions
General: Most adverse reactions develop soon after injection, however the possibility of delayed reactions cannot be ruled out. The most frequently reported adverse reactions following administration of Magnevist are shown in Table I.

Adverse reactions occurred in 11 of 319 (3.4%) pediatric patients receiving Magnevist in clinical trials (headache, vasodilatation, dizziness, diarrhea, ear pain, tachycardia, fever, edema, seizure, vomiting, nausea and urticaria). This adverse reaction profile is consistent with the adverse reaction profile observed in adults.

Magnevist will cause tissue irritation and pain if administered extravascularly.

Transient increases or decreases in blood pressure may occur after the administration of Magnevist. These changes are generally of little consequence although 3 clinically significant cases of hypotension have occurred 2 to 6 hours after Magnevist injection. A relationship to the contrast medium could not be determined, however caution should be exercised by the patient when driving or operating machinery.

Serious or severe adverse effects associated with Magnevist have been rare in clinical experience. Postmarketing anaphylactic reactions have been reported, but are very rare. Convulsions were reported in 3 patients with a history of seizures.

Laboratory Changes: Reversible mild elevations over baseline in serum iron and total bilirubin occur in most patients after receiving Magnevist. These changes do not appear to be clinically relevant. Other disturbances in laboratory values (transient increases in liver function tests) have not been associated with the use of Magnevist.

Adverse Drug Reaction Profile: The following adverse reactions, listed according to body system, have been reported after administration of Magnevist.

Cardiovascular: hypotension, vasodilatation, pallor, phlebitis, nonspecific ECG changes, substernal pain, angina.

CNS: headache, dizziness, agitation, paresthesia, tinnitus, visual field defect, convulsions, hyperesthesia.

Gastrointestinal: nausea, vomiting, gastrointestinal distress, stomach pain, thirst, increased salivation, taste abnormality.

Respiratory: dry mouth, throat irritation, rhinorrhea, wheezing, sneezing, laryngismus, cough, dyspnea/apnea.

Cutaneous/Mucous Membranes: rash, sweating, urticaria, pruritus.

Miscellaneous: injection site discomfort (coldness, burning, warmth, pain), teeth pain, generalized weakness, fever, localized edema, tiredness, anaphylactoid reactions (characterized by cardiovascular, respiratory and cutaneous symptoms), conjunctivitis.

Laboratory Tests: transient elevation of serum iron and bilirubin levels.

The following other adverse events were reported. A causal relationship has neither been established nor refuted.

Cardiovascular: hypertension, tachycardia, syncope, death related to myocardial infarction or other undetermined causes.

CNS: diplopia, migraine, anxiety, drowsiness, nystagmus, stupor.

Gastrointestinal: constipation, diarrhea, anorexia.

Cutaneous/Mucous Membranes: facial edema, erythema, epidermal necrolysis.

Miscellaneous: localized pain (back, ear, eye).

Magnevist - Symptoms And Treatment Of Overdose
Symptoms and Treatment: In the event of inadvertent overdosage or in the case of severely impaired renal function, Magnevist can be removed from the body by extracorporeal hemodialysis. tag_DosageDosage

Magnevist - Dosage And Administration
Special preparation of the patient for examination with gadopentetate meglumine is not required; however, precautionary measures should be taken with patients predisposed to seizure, e.g., close monitoring and availability of injectable anticonvulsants (see Precautions). The usual safety rules for MRI (e.g., exclusion of ferromagnetic vascular clips) must be observed.

Young children, infants and neonates may require sedation prior to undergoing an MRI examination, in order to eliminate movement artifacts.

The following dosage guidelines apply to adults and children (including neonates and infants):

Recommended Dose: 0.2 mL/kg (0.1 mmol/kg).

Route of Administration: i.v. (into a large vein, if possible).

Rate of Administration: 10 mL/min or as a bolus injection at 10 mL/15 sec.

Maximum Total Dose: 20 mL.

To ensure complete injection of the contrast medium, the injection should be followed by a 5 mL normal saline flush.

If strong clinical suspicion of an intracranial or intraspinal lesion persists, despite a normal MRI scan, the diagnostic yield of the examination may be increased by giving another injection of Magnevist equivalent to the original total dose within 30 minutes and performing MRI again.

Magnevist should not be drawn into the syringe until immediately before use. Any unused portion must be discarded upon completion of the procedure.

T1-weighted scanning sequences are particularly suitable for contrast-enhanced examinations.

Magnevist has been shown to be effective in a wide range of field strengths (0.14 to 1.5 Tesla).

Important Note: The imaging procedure should be completed within 1 hour since optimal contrast is generally observed in cranial investigations within 27 minutes following injection of Magnevist and in spinal investigations during the early postadministration phase (10 to 30 minutes).

In neonates and infants, optimal CNS contrast has been observed to persist for several hours after Magnevist administration.

All prescription drugs:

abilify accupril accutane acetaminophen aciphex actifed actonel actos acyclovir adalat adderall adipex advair advil albuterol alesse aleve allegra allopurinol amaryl ambien amiodarone amitriptyline amoxicillin amoxil amphetamine anacin aprazolam aricept asacol aspirin atenolol ativan atorvastatin atrovent augmentin avandia avapro avastin avelox azmacort
bactrim bactroban baycol benadryl bextra biaxin boniva bontril buspar buspirone
caduet campral camptosar capoten captopril cardizem cardura carisoprodol casodex catapress cefzil celebrex celexa cellcept cephalexin cialis cipro ciprodex clarinex claritin climara clindamycin clonazepam clonidine codeine codeprex combivent combivir concerta copaxone coreg coricidin cotrim coumadin cozaar crestor cubicin cyclobenzaprine cymbalta
darvocet demerol depakote desogen detrol dextromethorphan diazepam diclofenac didrex diflucan digoxin dilantin diltiazem dimetapp diovan diprivan ditropan doxazosin doxycycline drixoral duragesic dyazide
effexor elavil elocon eloxatin emend enalapril enbrel endocet engerix-b entex epogen epzicom erbitux ertaczo ery-tab erythromycin estradiol evista 
fabrazyme famotidine fazaclo fenofibrate fioricet fiorinal flexeril flomax flonase flovent fluoxetine fosamax fosrenol furosemide  
gabapentin gamimune gemfibrozil gemzar glipizide glucophage glucotrol glucovance glyburide glyburide guaifenesin guaifenex 
herceptin humalog humira hydroxyzine hyzaar  
ibuprofen imdur imitrex imodium inderal insulin integrilin iressa 
kaletra keflex kenalog keppra ketek klonopin kytril  
lamictal lamisil lanoxin lantus lasix lescol levaquin levitra levothyroxine levoxyl lexapro lidoderm lipitor lisinopril lithium lorazepam lortab lotensin lotrel lotrisone lovenox lupron luveris  
macrobid magnevist meclizine medroxyprogesterone meridia metformin methadone methamphetamine methotrexate methylphenidate methylprednisolone metoclopramide metoprolol metronidazole miacalcin minocycline mobic monopril morphine motrin myfortic  
naproxen nasacort nasonex natrecor neulasta neupogen neurontin nexium nifedipine nitrofurantoin norco nortriptyline norvasc  
omeprazole omnicef orthovisc oxybutynin oxycodone oxycontin oxytrol  
paraplatin patanol paxil pegasys penicillin pepcid percocet percodan percogesic phendimetrazine phenergan phentermine phenytoin plavix plendil potassium pravachol prednisone premarin prempro prevacid prilosec prinivil procrit promethazine propecia propofol propoxyphene propranolol protonix proventil provigil prozac pseudoephedrine pulmicort  
ranitidine rebetol reglan relafen relpax remeron remicade renagel renova rhinocort riomet risperdal risperidone ritalin rituxan rocephin rogaine roxicet  
sanctura seasonale sensipar serevent seroquel serzone singulair skelaxin soma somavert sonata spiriva spironolactone strattera striant sustiva synagis synthroid 
tamoxifen tavist taxol taxotere tegretol temazepam tenormin tenuate tequin terazosin tetracycline tiazac tindamax titralac tobradex topamax toprol tramadol trazodone triamcinolone triaminic triamterene tricor trileptal trimox triphasil trizivir truvada tylenol 
ultane ultracet ultram uroxatral
valium valtrex vaniqa vasotec velcade verapamil viagra vicodin vicoprofen vidaza viracept viread vytorin  
warfarin wellbutrin  
xalatan xanax xenical xifaxan xolair xopenex xyrem  
zanaflex zantac zavesca zelnorm zemplar zerit zestoretic zestril zetia ziac zithromax zocor zofran zoladex zoloft zometa zorbtive zosyn zovirax zyrtec zyvox